Blueprint Medicines
38 Sidney Street
Suite 200
Cambridge
Massachusetts
02139
United States
Tel: 617-374-7580
Website: http://www.blueprintmedicines.com/
Email: info@blueprintmedicines.com
About Blueprint Medicines
Blueprint Medicines is developing a new generation of highly selective and potent kinase therapies to dramatically improve the lives of patients with genomically defined diseases.Our approach is rooted in a deep understanding of the genetic blueprint of cancer and other diseases driven by the abnormal activation of kinases. We believe our ability to identify novel drivers of disease, coupled with our proprietary library of novel and diverse chemical compounds, uniquely enables us to craft kinase therapies against new and difficult-to-drug targets.
YEAR FOUNDED:
April 2011
LEADERSHIP:
CEO: Jeff Albers
CMO: Anthony L. Boral, M.D., PhD
CBO: Kate Haviland
CSO: Christoph Lengauer, PhD
JOBS:
Please click here for Blueprint job opportunities.
CLINICAL TRIAL:
Please click here for clinical trial information.
130 articles with Blueprint Medicines
-
Blueprint Medicines Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - September 06, 2022
9/6/2022
Blueprint Medicines Corporation announced that, effective September 1, 2022, the Compensation Committee of Blueprint Medicines' Board of Directors granted non-qualified stock options to purchase an aggregate of 18,170 shares of its common stock and an aggregate of 9,083 restricted stock units to thirteen new employees under Blueprint Medicines' 2020 Inducement Plan.
-
Blueprint Medicines’ Ayvakit is headed to the FDA for a new indication after the drug hit the mark in Part 2 of the PIONEER trial for non-advanced systemic mastocytosis.
-
Blueprint Medicines Announces Positive Top-line Results from PIONEER Trial of AYVAKIT® (avapritinib) in Patients with Non-Advanced Systemic Mastocytosis Achieving Primary and All Key Secondary Endpoints
8/17/2022
Blueprint Medicines Corporation (NASDAQ: BPMC) today announced positive top-line results from the registrational Part 2 of the PIONEER clinical trial of AYVAKIT®.
-
Blueprint Medicines Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) - Aug 04, 2022
8/4/2022
Blueprint Medicines Corporation announced that, effective August 1, 2022, the Compensation Committee of Blueprint Medicines' Board of Directors granted non-qualified stock options to purchase an aggregate of 29,359 shares of its common stock and an aggregate of 14,675 restricted stock units to fourteen new employees under Blueprint Medicines' 2020 Inducement Plan.
-
IDRx aims to create highly selective and aligned drug combinations to stop key tumor escape mechanisms that will support prolonged and durable responses to therapy.
-
Blueprint Medicines to Report Second Quarter 2022 Financial Results on Tuesday, August 2, 2022
7/26/2022
Blueprint Medicines Corporation (NASDAQ: BPMC) today announced that it will host a live conference call and webcast at 8:00 a.m. ET on Tuesday, August 2, 2022 to report its second quarter 2022 financial results and provide a corporate update.
-
Blueprint Medicines Publishes Inaugural Corporate Responsibility Report
7/14/2022
Blueprint Medicines Corporation (NASDAQ: BPMC) today published its first Corporate Responsibility Report.
-
Blueprint Medicines announced strategic financing collaborations with Sixth Street and Royalty Pharma for up to $1.25 billion to expand Blueprint's pipeline and pursue business development opportunities.
-
Blueprint Medicines Announces Transformative $1.25 Billion Strategic Financing Collaborations with Sixth Street and Royalty Pharma
6/30/2022
Strengthens balance sheet with significant non-dilutive, low-cost capital Expands ability to bring the promise of precision therapy to broad patient populations through internal R&D and strategic business development Propelled by global launches of AYVAKIT®/AYVAKYT® (avapritinib) and GAVRETO®.
-
Blueprint Medicines Reports Continued Progress Toward Goal of Transforming Treatment of Systemic Mastocytosis
6/9/2022
New analyses showing AYVAKIT® (avapritinib) significantly improved overall survival in advanced SM, when indirectly compared to real-world data for prior standard therapies, to be presented at EHA 2022 Congress.
-
Blueprint Medicines Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) - June 03, 2022
6/3/2022
Blueprint Medicines Corporation announced that, effective on June 1, 2022, the Compensation Committee of Blueprint Medicines' Board of Directors granted non-qualified stock options to purchase an aggregate of 47,587 shares of its common stock and an aggregate of 23,787 restricted stock units to twenty-seven new employees under Blueprint Medicines' 2020 Inducement Plan.
-
Blueprint Medicines Reports First Quarter 2022 Results
5/3/2022
Blueprint Medicines Corporation (NASDAQ: BPMC) today reported financial results and provided a business update for the first quarter ended March 31, 2022.
-
Blueprint Medicines to Report First Quarter 2022 Financial Results on Tuesday, May 3, 2022
4/26/2022
Blueprint Medicines Corporation today announced that it will host a live conference call and webcast at 8:30 a.m. ET on Tuesday, May 3, 2022 to report its first quarter 2022 financial results and provide a corporate update.
-
The initial program will focus on one degrader combined with multiple proprietary E3 ligase platforms and use VantAI’s geometric deep learning platform.
-
AstraZeneca and Daiichi Sankyo reported that their supplemental Biologics License Application (sBLA) for Enhertu was granted Priority Review by the U.S. Food and Drug Administration.
-
The American Association for Cancer Research (AACR) Annual Meeting is running from April 7-13 in New Orleans. Here’s a look at some of the preclinical and early-stage studies recently presented.
-
Blueprint Medicines to Showcase Broad Precision Therapy Pipeline at AACR Annual Meeting 2022
3/8/2022
Blueprint Medicines Corporation announced plans to present new clinical and preclinical data for multiple programs across its precision therapy portfolio at the American Association for Cancer Research Annual Meeting 2022 in New Orleans, April 8 to 13.
-
Blueprint Medicines Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) - Mar 04, 2022
3/4/2022
Blueprint Medicines Corporation announced that, effective on March 1, 2022, the Compensation Committee of Blueprint Medicines' Board of Directors granted non-qualified stock options to purchase an aggregate of 12,591 shares of its common stock and an aggregate of 6,293 restricted stock units to twelve new employees under Blueprint Medicines' 2020 Inducement Plan.
-
Blueprint Medicines Reports Fourth Quarter and Full Year 2021 Results
2/16/2022
Blueprint Medicines Corporation (NASDAQ: BPMC) today reported financial results and provided a business update for the fourth quarter and full year ended December 31, 2021.
-
Blueprint Medicines to Present at Upcoming Investor Conferences - Feb 11, 2022
2/11/2022
Blueprint Medicines Corporation announced its participation in the following upcoming investor conferences.